Enlivex halts oncology research, lays off 50% of staff; Moderna warns against TRC Capital mini-tender

En­livex Ther­a­peu­tics is stop­ping all clin­i­cal de­vel­op­ment of its on­col­o­gy drug can­di­dates as well as lay­ing off 50% of its work­force. The com­pa­ny plans to seek ex­ter­nal col­lab­o­ra­tions and out-li­cens­ing op­por­tu­ni­ties for its on­col­o­gy as­sets.

As of Dec. 2022, the Ness Ziona, Is­rael-based com­pa­ny had 77 em­ploy­ees. The com­pa­ny is re­fo­cus­ing its at­ten­tion in­to in­flam­ma­to­ry and au­toim­mune ther­a­pies, as per its sec­ond quar­ter re­port.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.